Ginkgo Bioworks: Streamlining the Process of Engineering Biology for Easier Product Creation.
February 9, 2023
Trending News ☀️
Ginkgo Bioworks ($NYSE:DNA) is a biotechnology company that specializes in engineering biology. Their mission is to revolutionize the way living organisms are designed, providing customers with the tools needed to turn their ideas into reality. Ginkgo strives to make this process easier by streamlining the engineering of biology and scaling their platform for programming cells. Ginkgo has developed a comprehensive B2B solution to help its customers create products more efficiently. They provide a strong foundry and large code library that can be used to create custom biological parts, devices, and systems. By collaborating closely with customers to fine-tune their product requirements, Ginkgo is able to provide reliable and cost-effective solutions. The company offers a wide range of services, from design and prototyping to testing and scale-up. This allows customers to quickly develop products and bring them to market.
In addition, Ginkgo offers a variety of training programs designed to give customers the skills they need to be successful in the field of engineering biology.
Market Price
The current media sentiment towards the company is mostly positive. On Wednesday, Ginkgo Bioworks stock opened at $2.0 and closed at $1.8, which was a drop of 8.5% from last closing price of 2.0. This drop in the stock price is likely due to the volatile nature of the stock market and does not necessarily reflect the company’s performance. Ginkgo Bioworks has developed a platform that enables customers to use software and biology to create customized products. This platform, known as “BioFactory”, enables customers to create products that are tailored to their specific needs by using a combination of software, hardware, and biological components. The platform is designed to be accessible to all customers, regardless of their background in biology or engineering. Ginkgo Bioworks has also developed a suite of services that assist customers in creating products. These services include data analysis, product design, and manufacturing support.
Additionally, Ginkgo Bioworks provides access to its library of biological parts and materials, which can be used to create custom products. Its platform and services make it easier for customers to develop products that are tailored to their specific needs. With its current media sentiment being positive and its stock having had only a slight decrease in value, Ginkgo Bioworks is well-positioned for future success in the industry. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…
| Total Revenues | Net Income | Net Margin |
| 527.91 | -3.59k | -701.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…
| Operations | Investing | Financing |
| -313.04 | -92.91 | -13.64 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.87k | 430.96 | 0.87 |
Key Ratios Snapshot
Some of the financial key ratios for Ginkgo Bioworks are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -694.5% |
| FCF Margin | ROE | ROA |
| -65.3% | -154.3% | -122.5% |
Analysis
GINKGO BIOWORKS is a biotechnology company, and GoodWhale provides investors with the ability to analyze its fundamentals. According to the Star Chart, GINKGO BIOWORKS has an intermediate health score of 6/10 considering its cashflows and debt, indicating that it is likely to safely ride out any crisis without the risk of bankruptcy. GINKGO BIOWORKS is classified as a ‘cheetah’ company, meaning that it has achieved high revenue or earnings growth but is considered less stable due to lower profitability. GINKGO BIOWORKS is strong in terms of assets and growth, but weak in terms of dividend and profitability. Investors looking for high growth potential may be interested in GINKGO BIOWORKS, but they should be aware of the company’s lack of dividend payments and lower profitability. Investors looking for stability may want to look elsewhere. Additionally, as GINKGO BIOWORKS is likely to experience some volatility due to its ‘cheetah’ classification, investors should be prepared for potential risks associated with such a situation. More…
Peers
The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.
– Abivax SA ($OTCPK:AAVXF)
Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
– Atreca Inc ($NASDAQ:BCEL)
Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.
– Kiromic BioPharma Inc ($NASDAQ:KRBP)
Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Summary
Ginkgo Bioworks is a biotechnology engineering company that has been gaining attention for its innovative approach to product creation. The company has seen positive sentiment from the market and its stock price dropped on the same day. Investors are encouraged to analyze Ginkgo Bioworks in more depth to better understand the company’s potential and risk profile. Doing so could help them decide if the company is a good investment opportunity and if so, how much to invest. Factors such as technological advances, growth potential and competitive dynamics should be considered.
Additionally, investors should keep an eye on market sentiment and stock price movements to get an idea of the company’s future direction.
